SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is experiencing a significant surge in trading volume and price action, with investors actively discussing potential institutional accumulation and the possibility of upcoming positive catalysts. Community members are closely monitoring the stock's ability to maintain these gains as it approaches key technical levels and institutional interest grows ahead of scheduled earnings.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to persistent volatility and intense debate among investors over its long-term growth versus ongoing short-selling pressure. The community is actively discussing the company's competitive position against rivals like Monster and the impact of its distribution partnership with PepsiCo.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing significant volatility and community division as investors react to a recent multi-million dollar treasury exploit and ongoing concerns about potential delistings. While some participants are aggressively "buying the dip" in anticipation of a broader market bull run, others are voicing frustration over steady price declines and skepticism regarding the project's long-term utility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to community debate surrounding reports that the company is considering charging high-dollar monthly fees to provide institutional investors with expedited access to Truth Social posts. Investors and community members are sharply divided over the firm's monetization strategies, while ongoing political discourse regarding election integrity continues to drive intense engagement across the platform.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is seeing significant market activity as investors speculate on a potential path forward for the company's RP1 candidate following recent collaborative discussions with the FDA. While some traders are betting on a positive outcome regarding the resubmission of the biologics license application, the community remains divided, with debates intensifying over the company's regulatory history and the substantial short interest currently surrounding the symbol.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as it battles Nvidia for the title of the world's most valuable company, with investors rotating into its stock as a perceived defensive safe haven amid broader tech volatility. While the community remains divided over its high valuation and limited AI innovation, strong institutional buying and positive analyst upgrades are driving sentiment, prompting heated debates between bullish traders following the breakout and bearish voices calling the move a manipulated market-stabilization tactic.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA approval of Auvelity for the treatment of agitation associated with Alzheimer's disease dementia, a milestone that significantly expands the drug's addressable market. Investors are actively discussing the potential for multi-billion dollar peak sales and the stock's long-term growth trajectory as the company transitions into a new phase of commercial execution and pipeline development.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing intense selling pressure, with community members expressing frustration over management decisions and executive compensation while the stock struggles to find a floor. Investors are closely monitoring key support levels near $30-$33, debating whether the current pullback represents a strategic accumulation opportunity for AI infrastructure exposure or a continued slide driven by market-wide volatility and liquidity concerns.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently facing heightened market volatility driven by a patent infringement lawsuit from Mesoblast and uncertainty surrounding its upcoming FDA advisory committee meeting for its lead DMD treatment, Deramiocel. While some investors are concerned by these legal and regulatory pressures, the community remains actively divided, with many long-term holders dismissing the negative sentiment as short-seller manipulation and maintaining conviction in the drug's Phase 3 clinical data.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to the European Medicines Agency's approval for the commercial manufacturing of its GP2 peptide, a significant step toward streamlining its global Phase 3 FLAMINGO-01 breast cancer trial. Community discussion remains focused on the trial's expanded scale, the strategic implications for a potential partnership or buyout, and the ongoing volatility driven by high short interest and anticipation of interim clinical data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD PR Newswire BOCA RATON, Fla...

Stem Wins The smarter E AWARD 2026 for PowerTrack Energy Management System

Stem, Inc. (NYSE: STEM), a global leader in AI-enabled clean energy software and services, today announced that its PowerTrack Energy Management System (EMS) has won The smarter E AWARD 2026 in the Smart Integrated Energy category. Organized by Solar Promotion International GmbH and Freiburg...

Stem Launches AIONA, a Dedicated AI Services Offering Built for Operational Impact

Stem Inc. (NYSE: STEM), a global leader in AI-enabled clean energy software and services, today announced the launch of AIONA, Stems AI services offering developed in direct response to growing customer and market demand for practical, execution-focused artificial intelligence solutions. AIONA...

Stem Brings PowerTrack EMS to Latin Americas Utility-Scale Hybrid Market with Granja Solar Project in Chile

Stem, Inc. (NYSE: STEM), a global leader in AI-enabled clean energy software and services, today announced that Copec Flux, the renewable energy subsidiary of Copec S.A., is deploying Stems PowerTrack Energy Management System (EMS) at the Granja Solar project in Chile. This development expands...

Bluesphere Ventures Selects Stem for New York VDER Storage Advisory

Stem, Inc. (NYSE: STEM), a global leader in AI-enabled clean energy software and services, today announced that it has entered into a new services agreement with Bluesphere Ventures to support its...

STEM’s Revenue Miss Was Not The Only Thing Worrying Retail Traders

Equity

Stem reported a quarterly revenue of $29 million, a 11% dip year-over-year, primarily due to the absence of battery hardware resales.

Stem, Inc. (STEM) Reports Q1 Loss, Misses Revenue Estimates

Stem (STEM) delivered earnings and revenue surprises of +9.36% and -22.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Stem Announces First Quarter 2026 Results

Stem, Inc. (Stem, we or the Company) (NYSE: STEM), a global leader reimagining technology to support the energy transition, announced today its results for the quarter ended March 31, 2026. Financial...

Stem and Nuvation Energy Enter into Agreement to Deliver North American-Made BESS Control Solution

Stem, Inc. (NYSE: STEM), a global leader in AI-enabled clean energy software and services, today announced a co-marketing agreement with Nuvation Energy, a North American provider of battery...

Stem (STEM) Projected to Post Earnings on Wednesday

Stem (NYSE:STEM) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-stem-inc-stock...

Stem, Inc. engages in the provision of an energy storage system, hardware, ongoing software platform and professional services, and solar asset performance monitoring and control. The company was founded in 2009 and is headquartered in Houston, TX.

Stem Inc - Ordinary Shares - Class A

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$6.26
Prev Close	$6.32
Open	$6.15
Dividend Yield	0.00%
50-Day Moving Average	$8.32
Beta	2.38
Avg. Volume	139,946.05
PE Ratio	-0.72

52-Week High	$32.23
52-Week Low	$6.20
Market Capitalization	$56.61M
EPS (Annual)	-$9.18
Price to Book	-0.20
Revenue Per Employee	$369,423.17

Feed

News

Sentiment

Earnings

Fundamentals

Info

STEMStem Inc

Latest STEM News